MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Strona główna・Stock List・Kura Oncology Inc

Kura Oncology Inc

Open

SectorHealthcare

9.02 -1.2

Buy Sell

Overview

Share price change

24h

Current

Min

8.88

Max

9.24

Key metrics
By Trading Economics
Income	-6.9M -81M
Sales	-3.4M 17M
Profit margin	-467.23
Employees	260
EBITDA	-12M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+207.77% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	19M 774M
Previous open	10.22
Previous close	9.02

News Sentiment

By Acuity

60%

40%

310 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.575 / 6.6 Support & Resistance

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 kwi 2026, 23:36 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 kwi 2026, 23:24 UTC

Hot Stocks

Stocks to Watch: Gloo, Broadcom, GitLab

14 kwi 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 kwi 2026, 21:32 UTC

Major Market Movers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 kwi 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 kwi 2026, 22:54 UTC

Earnings

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 kwi 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 kwi 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 kwi 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

14 kwi 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 20:32 UTC

Hot Stocks

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 kwi 2026, 19:59 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 kwi 2026, 19:21 UTC

Market Talk

Major News Events

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 kwi 2026, 19:09 UTC

Acquisitions, Mergers, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 kwi 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 kwi 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

207.77% upside

12 Months Forecast

Average 28.13 USD 207.77%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

310 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.